Sage Therapeutics Files 8-K on Financials
| Field | Detail |
|---|---|
| Company | Sage Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Sage Therapeutics filed an 8-K on 4/29/25 for financial reporting.
AI Summary
On April 29, 2025, Sage Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided text.
Why It Matters
This filing indicates Sage Therapeutics is providing updates on its financial performance and condition to the SEC, which is important for investors to assess the company's health.
Risk Assessment
Risk Level: low — The filing is a standard SEC disclosure and does not contain specific negative or positive news that would immediately alter risk.
Key Players & Entities
- Sage Therapeutics, Inc. (company) — Registrant
- April 29, 2025 (date) — Date of Report
- 001-36544 (other) — SEC File Number
- 55 Cambridge Parkway, Cambridge, MA 02142 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Sage Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on Sage Therapeutics, Inc.'s Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on April 29, 2025.
What is Sage Therapeutics, Inc.'s principal executive office address?
Sage Therapeutics, Inc.'s principal executive office is located at 55 Cambridge Parkway, Cambridge, MA 02142.
What is the SEC file number for Sage Therapeutics, Inc.?
The SEC file number for Sage Therapeutics, Inc. is 001-36544.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 29, 2025 regarding Sage Therapeutics, Inc..